Finishing events

Identify the three possible paths from the start event A to the finish event F for the contract shown by the network diagram in Fig. 6.49. Identify the critical path and the float time in each path. 

The longest time from the start event to the finish event is 24 hours, and... 

Activities D-G and F G are dummy activities which take no time to complete but Indicate a logical link only. This means that in this case, once the activities preceding events D and F have been completed, the contract will not be held up by work associated with these particular paths and they will progress naturally to the finish event. 

The other reason for not using percent completion is that it involves no commitment on the part of individuals responsible for the event to finish at any particular time. To report that you are X per cent complete on an event is a subjective evaluation of history, not a statement of future plans and intentions. Thus, we often experience the phenomenon of completion percentages that increase by ever-smaller amounts and never quite reach 100 per cent. 

Ethylene oxide is used in the manufacture of raw materials and can be used to sterilize the surface of finished products and containers. Unfortunately, ethylene oxide is a genotoxic carcinogen and its use is not accepted without justification. In any event, tight controls are required on residues of ethylene oxide and its halohydrin-related substances. For raw materials the amount of these residues is limited to 1 and 50 pig/g, respectively for finished products 1 and 50 pg/g, respectively (with any affected ingredients subject to the control limits for raw materials) and for containers, based on simulated use, 1 and 50 pg/mL container volume, respectively. 

In an elegant paper, Gerdes et al. [59] examined whether the risk of death or a major coronary event in survivors of myocardial infarction (MI) was related to the apo E genotype and whether risk reduction brought about by simvastatin was different between genotypes. They analyzed 5.5 years of follow-up data of 966 Danish and Finish myocardial infarction survivors enrolled in the Scandinavian Simvastatin Survival Study and found that MI survivors with the apo E4 allele have a nearly 2-fold increased risk of death, and that treatment with simvastatin abolished excess mortality. They concluded that the effect of apo E4 may involve mechanisms unrelated to serum lipoproteins because... 

A local builder was contracted to instal the floor. Part of the specification stated that those areas of the internal wall surfaces that would abut the concrete floor should be cement rendered, with as flat a finish as possible, before the base concrete was poured. In the event, the standard of rendering was poor and uneven. The other stages in the installation of the concrete floor were performed satisfactorily. 

Hardware requirements — The system controller responsible for synchronizing the events is defined as LC System 1. It requires at least two time event outputs to trigger the injection of LC System 2 and start MS data collection. If MS fails, the injection of LC System 1 should be inhibited. Autosampler with ready-in, alarm-in, and stop inputs indicate capability to be stopped remotely. The autosampler of LC System 2 must be able to prepare a sample before the run from LC System 1 is finished and hold the sample in the injector loop until an injection signal is received. A manual injection input devices indicates that the autosampler can perform the required function. 

In order to reflect these lead times, the concept of a timestamp is introduced. Timestamp is used in computer science documenting the system time when a certain event or transaction occurs e.g. for logging events (N.N. 2007). In the context of future inventory value planning, the time-stamp marks the period, when the first raw material has reached a certain stage in the value chain network included into a specific product. In the example illustrated in fig. 57, the raw material is processed in the same period to be converted into product 1. Therefore, all four value chain steps indexed from one to four occur in the same period and have the same time-stamp one. Conversion into product 2, however, requires additional time caused by production lead times, safety inventory and/or transportation time, that the steps indexed with five and six have a time stamp of two. The timestamp reflects that the inventory value of product 2 is not based on the raw material costs from the same period but based on the raw material costs from the previous period in order to reflect the lead time. Consequently, value chain indices and timestamps are defined for all steps and can cover multiple periods reflecting that raw materials in a global complex multi-stage value chain network can take several months, until they are sold as part of a finished product to the market. 

Prof. Serratosa had also received the assurance of Prof. Nuria Casamitjana that, in any event, she would finish up the job and indeed, despite all the difficulties, she has fulfilled her commitment. She has recovered all materials left on disk by Prof. Serratosa, revised and updated all references, rewritten parts of some chapters and made altogether, I believe, an excellent job. 

T7ie race was a disaster. It was pouring with rain all day and by the time my event started the course was churned into a quagmire and at one point looked like a river. I am a fluid runner and this was a course for sloggers... It was desperately tough... I think I finished twenty-seventh ... 

Is there a clear description of what source data will be recorded directly into the CRF and what will be recorded in the medical records Normally, the protocol identification number, the date of consent, the date of commencement of the study, the visit dates, the start and finish dates of the administration of study drug and/or treatment, concurrent medication, adverse events and... 

Are there clear instructions for reporting of adverse events and serious adverse events (SAEs) There should be full instructions for the reporting of SAEs (including addresses and fax numbers), with time limits. It should be clear that these rules also apply to SAEs that occur in subjects who have finished the study. All SAEs that come to the knowledge of the trialist should be reported unless the protocol provides guidance or time limit when the authors can justify that the occurrence of the SAE could not be related to the treatment received in the clinical trial. In a blinded study, there should be clear instructions on when and by whom the code for a particular study subject should be unblinded in an emergency. 

The protocol should specify what should be recorded directly into the CRF and what will also be recorded in the medical records. The CRF will contain all the pertinent data associated specifically with the clinical trial but some will be repeated in the medical records, for example, the protocol identification number, date of consent, date of commencement of the study, key baseline medical findings, visit dates, start and finish dates of the study drug/placebo or treatment, concurrent medication, adverse events and key efficacy and any unscheduled or scheduled actions or interventions (such as escape medication). Additional information obtained from biopsy reports, radiographs and similar documents will provide confirmation that the data in the CRF are recorded correctly. Monitors, QA auditors and inspectors need to see all the medical records available to the investigator. It is not appropriate to create copies of data from CRFs or checklists derived from medical records and claim that these are source documents. 

The exact events that make up the Candidate Physical Ability Test vary from place to place, but the tasks you have to perform are almost always job-related—they are a lot like the physical tasks you will actually have to perform as a firefighter. Some tests are set up as obstacle courses others consist of a group of stations. In some, you are timed from start to finish with no breaks others allow a break period between stations. The tests are timed. Your performance on the test is scored depending on that time. Often you have to wear full (heavy) protective gear, including an air pack, throughout these events. Here is an example of the events in a test that you would typically have ten minutes, 20 seconds to complete ... 

Risk assessment starts with risk identification, a systematic use of available information to identify hazards (i.e., events or other conditions that have the potential to cause harm). Information can be from a variety of sources including stakeholders, historical data, information from the literature, and mathematical or scientific analyses. Risk analysis is then conducted to estimate the degree of risk associated with the identified hazards. This is estimated based on the likelihood of occurrence and resultant severity of harm. In some risk management tools, the ability to detect the hazard may also be considered. If the hazard is readily detectable, this may be considered a factor in the overall risk assessment. Risk evaluation determines if the risk is acceptable based on specified criteria. In a quality system environment, criteria would include impact on the overall performance of the quality system and the quality attributes of the finished product. The value of the risk assessment depends on how robust the data used in the assessment process is judged to be. The risk assessment process should take into account assumptions and reasonable sources of uncertainty. Risk assessment activities should be documented. 

There should be a sampling plan for finished excipient testing. The sampling plan should be in accordance with the in-process sampling requirements outlined above. It is important that if only one sample from the finished batch is taken, that it be representative of the excipient. This is usually not possible if the lot is not homogeneous. In that event, it is important to establish a sampling plan that assures sufficient samples are taken so that with all samples in conformance, the entire excipient batch is known to be conforming. 

Even when no violative residues are found, the carcasses usually depreciate in value a great deal while awaiting the test results. To reduce testing time, the producers may apply to an approved laboratory to have the samples analyzed at their own expense. In the event a violative residue is found, the producer has to submit another group of animals for residue evaluation. This procedure may be repeated until analysis data of tissue samples indicate a residue-free status. In the meantime, the livestock producer is often confronted with increased production costs due to overcrowding caused by inability to market the animals on a timely basis. In addition, weight gains are slowed, feed efficiency becomes poorer, and the value of the product is lowered because of accumulation of excessive finish. 

In the event that any equipment is found to be out of calibration, the results of the finished products released prior to that determination are reviewed for disposition. 

---